A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Site NZ64001, Grafton

Memorial Sloan Kettering, New York

Weill Cornell Medical Center, New York

Site IT39009, Genova

University of Pennsylvania, Philadelphia

University of Maryland Medical Systems, Baltimore

Johns Hopkins Hospital, Baltimore

Wake Forest Baptist Health, Winston-Salem

University of North Carolina, Chapel Hill

Duke University Medical Center, Durham

Emory University, Atlanta

Northside, Atlanta

Augusta University, Augusta

University of Florida, Gainesville

University of Miami, Miami

H. Lee Moffitt Cancer Center, Tampa

University of Alabama at Birmingham, Birmingham

Vanderbilt University Medical Center, Nashville

Ohio State University, The, Columbus

University Hospitals of Cleveland Medical Center, Cleveland

Cleveland Clinic, Cleveland

Indiana Blood and Marrow Transplant, Indianapolis

Karmanos Cancer Center, Detroit

Medical College of Wisconsin, Milwaukee

University of Wisconsin Hospital and Clinics, Madison

University of Minnesota School of Medicine, Minneapolis

Mayo Clinic, Rochester

Loyola University Medical Center, Maywood

Northwestern Memorial Hospital, Chicago

Rush University Medical Center, Chicago

Washington University in St. Louis, St Louis

University of Nebraska Medical Center, Omaha

Baylor College of Medicine, Houston

Huntsman Cancer Institute, Salt Lake City

Intermountain BMT, Salt Lake City

Mayo Clinic, Phoenix

Virginia G Piper Cancer Center, Scottsdale

University of California San Francisco, San Francisco

Stanford University, Stanford

Oregon Health and Science University, Portland

Fred Hutchinson Cancer Research Center, Seattle

Yale University School of Medicine, New Haven

University of Kansas Medical Center, Kansas City

Massachusetts General Hospital, Boston

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

University of Massachusetts, Worcester

West Virginia University Hospital, Morgantown

Site AU61001, Liverpool

Site AU61002, Melbourne

Site AU61004, Westmead

Site BE32003, Brussels

Site BE32004, Ghent

Site CA15004, Hamilton

Site CA15003, Montreal

Site DK45002, Aarhus

Site DK45001, Copenhagen

Site FR33007, Lille

Site FR33004, Lyon

Site FR33005, Paris

Site FR33008, Pessac

Site FR33010, Vandœuvre-lès-Nancy

Site DE49006, Cologne

Site DE49002, Düsseldorf

Site DE49003, Halle

Site DE49005, Hamburg

Site DE49007, Mainz

Site DE49004, Münster

Site GR30004, Athens

Site GR30003, Rio

Site GR30001, Thessaloniki

Site IT39005, Bergamo

Site IT39006, Bologna

Site IT39002, Milan

Site IT39007, Milan

Site IT39011, Pescara

Site IT39003, Roma

Site IT39004, Udine

Site JP81014, Anjo

Site JP81011, Nagoya

Site JP81018, Sapporo

Site JP81021, Kobe

Site JP81012, Nishinomiya

Site JP81002, Isehara

Site JP81007, Yokohama

Site JP81010, Sendai

Site JP81006, Suita

Site JP81008, Shimotsuke

Site JP81013, Bunkyo-ku

Site JP81004, Chuo-ku

Site JP81016, Minato-ku

Site JP81020, Shinjuku-ku

Site JP81001, Fukuoka

Site JP81003, Fukuoka

Site JP81015, Kyoto

Site JP81017, Okayama

Site JP81005, Osaka

Site NZ64002, Christchurch

Site PL48004, Warsaw

Site KR82001, Seoul

Site KR82002, Seoul

Site KR82003, Seoul

Site KR82004, Seoul

Site KR82005, Seoul

Site ES34005, Barcelona

Site ES34006, Salamanca

Site ES34007, Santander

Site ES34002, Valencia

Site TW88603, Taichung

Site TW88602, Taipei

Site TW88605, Taoyuan District

Site GB44010, Birmingham

Site GB44003, Bristol

Site GB44004, London

Site GB44002, Manchester

Site GB44001, Sutton

Site ES34004, Barcelona

Site GB44009, Glasgow